• 1. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Carbazoles

Professional Introduction to 1-Hydroxy Carvedilol (CAS No. 146574-41-6)

1-Hydroxy Carvedilol, with the chemical identifier CAS No. 146574-41-6, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This metabolite of the well-known β-blocker Carvedilol, has garnered attention due to its unique pharmacological properties and potential therapeutic applications. The compound belongs to the class of hydroxylated derivatives, which often exhibit distinct biological activities compared to their parent molecules. In recent years, advancements in metabolic studies and drug metabolism research have highlighted the importance of 1-Hydroxy Carvedilol as a key intermediate and possibly an active pharmaceutical ingredient (API) in certain therapeutic contexts.

The synthesis and characterization of 1-Hydroxy Carvedilol have been subjects of extensive research, particularly in understanding the metabolic pathways of Carvedilol. Carvedilol, a non-selective β-adrenergic antagonist with α1-blocking properties, is widely used for its cardiovascular benefits, including the treatment of hypertension, heart failure, and myocardial infarction. The metabolic conversion of Carvedilol to its primary metabolites, such as 1-Hydroxy Carvedilol and carvacrol glucuronide, plays a crucial role in its overall pharmacokinetics. Studies have demonstrated that 1-Hydroxy Carvedilol retains some of the pharmacological effects of Carvedilol, making it a subject of interest for further pharmacological exploration.

Recent research has delved into the pharmacodynamic effects of 1-Hydroxy Carvedilol, particularly focusing on its cardiovascular and anti-inflammatory properties. Preclinical studies suggest that 1-Hydroxy Carvedilol may exhibit additional benefits beyond those of Carvedilol, such as enhanced antioxidant activity and modulation of inflammatory pathways. These findings are particularly relevant in the context of chronic cardiovascular diseases, where multifaceted therapeutic approaches are often required. The ability of 1-Hydroxy Carvedilol to interact with multiple biological targets makes it a promising candidate for developing novel therapeutic strategies.

In addition to its cardiovascular effects, investigations into the potential role of 1-Hydroxy Carvedilol in other disease areas have emerged. For instance, studies have explored its potential anti-cancer properties, suggesting that it may inhibit tumor growth and induce apoptosis in certain cancer cell lines. This is attributed to its ability to modulate signaling pathways involved in cell proliferation and survival. While these findings are still in the early stages of research, they highlight the broad therapeutic potential of 1-Hydroxy Carvedilol.

The analytical chemistry of 1-Hydroxy Carvedilol has also seen significant advancements, particularly in terms of detection and quantification techniques. High-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy are commonly employed methods for characterizing this compound. These techniques not only aid in confirming the structure of 1-Hydroxy Carvedilol but also enable precise measurement of its concentrations in biological samples. Such analytical methodologies are essential for understanding its pharmacokinetic behavior and for developing reliable bioavailability studies.

The regulatory landscape for compounds like 1-Hydroxy Carvedilol is another critical aspect that influences its development and commercialization. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent guidelines for assessing the safety and efficacy of new pharmaceutical entities. Given that 1-Hydroxy Carvedilol is a metabolite of an already approved drug (Carvedilol), it may benefit from certain regulatory advantages under specific conditions. However, comprehensive toxicological studies are still required to fully evaluate its safety profile before any clinical trials can be initiated.

Future directions in research on 1-Hydroxy Carvedilol include exploring its potential as a prodrug or combination therapy with other drugs. Prodrug strategies involve converting a less active or non-pharmacologically active compound into an active form within the body, which can enhance bioavailability or targeted delivery. Additionally, combination therapies involving multiple drugs acting on different pathways may offer synergistic effects, particularly in treating complex diseases like cardiovascular disorders and cancer.

The role of computational chemistry and molecular modeling in understanding the interactions between 1-Hydroxy Carvedilol and biological targets has also gained prominence. These computational approaches can predict binding affinities, identify potential drug-drug interactions, and optimize lead structures for further development. By leveraging computational tools alongside experimental data, researchers can accelerate the discovery process and reduce costs associated with traditional drug development methods.

In conclusion,1-Hydroxy Carvedilol (CAS No. 146574-41-6) represents a fascinating compound with diverse pharmacological applications. Its relationship with parent drug Carvedilol, combined with emerging research findings on its metabolic pathways and therapeutic potential, positions it as a valuable candidate for further exploration in pharmaceutical research. As scientific understanding continues to evolve, it is likely that additional insights into the mechanisms and applications of this compound will emerge, contributing to advancements in medicine.

• 123372-14-5((R)-(+)-O-Desmethyl Carvedilol)
• 918903-20-5(Carvedilol Bis-carbazole)
• 1261395-96-3(4-Hydroxycarvedilol D5)
• 142227-51-8(5’-Hydroxyphenyl Carvedilol)
• 142227-49-4(4’-Hydroxyphenyl Carvedilol)
• 146574-43-8(3-Hydroxy Carvedilol)
• 72956-44-6(O-Desmethyl Carvedilol)
• 123372-13-4((S)-(-)-O-Desmethyl Carvedilol)
• 95094-00-1((S)-Carvedilol)
• 95093-99-5((R)-Carvedilol)